Skip to main content
padlock icon - secure page this page is secure

Design, Synthesis, and Antibacterial Activity of Novel Carbacephems

Buy Article:

$68.00 + tax (Refund Policy)

Syntheses of (±)-cis-3-hydroxycarbonyl-7-(phenylacetamido)carbacephem (10), (±)-cis-3- methoxycarbonyl-7-(phenylacetamido)carbacephem (11), (±)-cis-2-chloro-3-hydroxycarbonyl-7-(phenylacetamido) carbacephem (14), and (±)-cis-2-chloro-3-methoxycarbonyl-7-(phenylacetamido)carbacephem (15) were accomplished. These four heretofore undescribed compounds 10, 11, 14, and 15 showed notable activity against Staphylococcus aureus FDA 209P, Escherichia coli ATCC 39188, Pseudomonas aeruginosa 1101-75, Klebsiella pneumoniae NCTC 418 as well as the β-lactamase producing organisms E. coli A9675, P. aeruginosa 18S-H and methicillin-resistant organism S. aureus 95. The electronic activation of lactam moieties of 11 and 15 enhanced remarkably their antibacterial activity relative to those of the 10 and 14. The chlorine atom in 14 and 15, acting as an effective leaving group, also resulted in an increment in the biological activity in comparison with those of the parent carbacephemes 10 and 11. The mode of action related to 14 and 15 can be explained by a non-classical [1,4]-elimination process.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cephalosporin; antibacterial; antibiotic; b-Lactam; b-Lactamase; carbacephem

Document Type: Research Article

Affiliations: TaiGen Biotechnology, 138 Shin Ming Rd., Neihu Dist., Taipei, Taiwan 114, R. O. C.

Publication date: March 1, 2006

More about this publication?
  • Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more